Matous Hrdinka

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3823078/publications.pdf

Version: 2024-02-01

26 papers	968 citations	623734 14 h-index	610901 24 g-index
26 all docs	26 docs citations	26 times ranked	1734 citing authors

#	Article	IF	Citations
1	SPATA2 Links CYLD to LUBAC, Activates CYLD, and Controls LUBAC Signaling. Molecular Cell, 2016, 63, 990-1005.	9.7	130
2	CYLD Limits Lys63- and Met1-Linked Ubiquitin at Receptor Complexes to Regulate Innate Immune Signaling. Cell Reports, 2016, 14, 2846-2858.	6.4	128
3	The Met1-Linked Ubiquitin Machinery: Emerging Themes of (De)regulation. Molecular Cell, 2017, 68, 265-280.	9.7	107
4	Inflammatory Signaling by NOD-RIPK2 Is Inhibited by Clinically Relevant Type II Kinase Inhibitors. Chemistry and Biology, 2015, 22, 1174-1184.	6.0	101
5	Venetoclax: A new wave in hematooncology. Experimental Hematology, 2018, 61, 10-25.	0.4	73
6	SCIMP, a Transmembrane Adaptor Protein Involved in Major Histocompatibility Complex Class II Signaling. Molecular and Cellular Biology, 2011, 31, 4550-4562.	2.3	63
7	Small molecule inhibitors reveal an indispensable scaffolding role of <scp>RIPK</scp> 2 in <scp>NOD</scp> 2 signaling. EMBO Journal, 2018, 37, .	7.8	55
8	Membrane microdomains in immunoreceptor signaling. FEBS Letters, 2014, 588, 2392-2397.	2.8	44
9	PAG - a multipurpose transmembrane adaptor protein. Oncogene, 2014, 33, 4881-4892.	5.9	41
10	Inhibitor of apoptosis proteins in human health and disease. Genes and Immunity, 2019, 20, 641-650.	4.1	39
11	A New Type of Membrane Raft-Like Microdomains and Their Possible Involvement in TCR Signaling. Journal of Immunology, 2010, 184, 3689-3696.	0.8	37
12	Synaptonuclear messenger <scp>PRR</scp> 7 inhibits câ€Jun ubiquitination and regulates <scp>NMDA</scp> â€mediated excitotoxicity. EMBO Journal, 2016, 35, 1923-1934.	7.8	33
13	Intercellular Mitochondrial Transfer in the Tumor Microenvironment. Cancers, 2020, 12, 1787.	3.7	25
14	LST1/A Is a Myeloid Leukocyte-specific Transmembrane Adaptor Protein Recruiting Protein Tyrosine Phosphatases SHP-1 and SHP-2 to the Plasma Membrane. Journal of Biological Chemistry, 2012, 287, 22812-22821.	3.4	21
15	Systematic analysis of the <scp>IL</scp> â€17 receptor signalosome reveals a robust regulatory feedback loop. EMBO Journal, 2020, 39, e104202.	7.8	16
16	Acute intermittent porphyriaâ€ƒâ€“â€ƒimpact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties. FEBS Journal, 2009, 276, 2106-2115.	4.7	12
17	PRR7 Is a Transmembrane Adaptor Protein Expressed in Activated T Cells Involved in Regulation of T Cell Receptor Signaling and Apoptosis. Journal of Biological Chemistry, 2011, 286, 19617-19629.	3.4	11
18	A Birdâ€™s-Eye View of Cell Sources for Cell-Based Therapies in Blood Cancers. Cancers, 2020, 12, 1333.	3.7	9

#	Article	IF	Citations
19	Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. Cells, 2021, 10, 967.	4.1	9
20	The Transmembrane Region Is Responsible for Targeting of Adaptor Protein LAX into â€œHeavy Raftsâ€. PLoS ONE, 2012, 7, e36330.	2.5	5
21	Normal Development and Function of T Cells in Proline Rich 7 (Prr7) Deficient Mice. PLoS ONE, 2016, 11, e0162863.	2.5	3
22	Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine. Blood Advances, 2021, , .	5.2	3
23	Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. Haematologica, 2021, 106, 601-604.	3.5	2
24	Identification of Deubiquitinase OTUD1 As a Novel Player in Resistance of Multiple Myeloma to Bortezomib. Blood, 2019, 134, 5526-5526.	1.4	1
25	Molecular pathology of heme biosynthesis. Porphobilinogen deaminase (PBGD): Novel mutations in Czech and Slovak patients with acute intermittent porphyria (AIP). FASEB Journal, 2006, 20, .	0.5	0
26	Identification of Novel Regulatory Pathway for Immunoglobulin Production Provides Rational Treatment for Bortezomib-Resistant Multiple Myeloma Patients. Blood, 2020, 136, 40-42.	1.4	0